Studies in non-IBC breast cancer cell lines have suggested a link between ER status, GLI1 levels and survival, and shown that GLI1 silencing in ER negative breast cancer markedly reduces survival (Zhao et al, 2009; Xu et al, 2010) and invasiveness (Kameda et al, 2009; Souzaki et al, 2011). This evidence concerns the gene GLI1 and breast carcinoma.